RxDoctor Payments DataLook up a doctor →

Grace Forde, MD

Pain Medicine · New Hyde Park, NYNPI 1508861816

Payments from drug & device makers

$397,724in general payments, 2019–2025

Across 1,100 payments — averaging $361.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$189K
  • Lilly USA, LLC$102K
  • Amgen$44K
  • Teva Pharmaceuticals USA, Inc.$37K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$9K
  • GRT US Holding, Inc.$9K
  • plus $7K from 48 others
$983in research payments, 2019–2025

Across 4 payments — averaging $245.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$983

What the payments were for

  • Consulting fees$30,8339%
  • Speaking & faculty fees$279,97279%
  • Grants$440%
  • Travel & lodging$21,1426%
  • Food & beverage$23,0996%
  • Education$3580%
  • Gifts$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)360$189,381
Lilly USA, LLC171$101,744
Amgen(2 entities)106$43,839
Teva Pharmaceuticals USA, Inc.76$37,418
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC35$9,249
GRT US Holding, Inc.27$8,988
Scilex Pharmaceuticals Inc.50$891
Pfizer28$883
Collegium Pharmaceutical, Inc.48$642
Kyowa Kirin, Inc.3$382
Biohaven Pharmaceutical Holding Company Ltd.17$329
Novartis22$309
Lundbeck LLC12$306
Medtronic4$297
Tersera Therapeutics LLC9$226
Sentynl Therapeutics, Inc.18$199
Hikma Pharmaceuticals USA12$193
Avanir Pharmaceuticals, Inc.4$180
Zyla Life Sciences, Inc.15$168
Supernus Pharmaceuticals, Inc.8$161
Tonix Medicines, Inc.2$154
UCB, Inc.2$152
Biohaven Pharmaceuticals, Inc.8$152
Harmony Biosciences LLC4$128
Biodelivery Sciences International, Inc.7$122
Takeda Pharmaceuticals U.S.A., Inc.1$120
Assertio Therapeutics, Inc.6$91
Eisai Inc.4$78
SPR Therapeutics, Inc1$72
Redhill Biopharma Inc.4$71
Axsome Therapeutics, Inc.1$71
Boston Scientific1$70
Promius Pharma LLC3$54
Averitas Pharma Inc.2$53
Currax Pharmaceuticals LLC3$50
AstraZeneca3$47
Shionogi Inc2$44
Bausch Health US, LLC3$39
Almatica Pharma LLC2$38
Otsuka America Pharmaceutical, Inc.1$35
Amneal Pharmaceuticals LLC2$33
Neurocrine Biosciences, Inc.1$31
Forte Bio-pharma LLC1$24
Nevro Corp.1$23
Antares Pharma, Inc.1$22
Daiichi Sankyo Inc.1$22
West Therapeutics Development, LLC1$21
Merz Pharmaceuticals, LLC1$20
Grifols USA, LLC1$20
IBSA Pharma Inc.1$20
Virtus Pharmaceuticals LLC1$19
Jazz Pharmaceuticals Inc.1$16
Merck1$15
Pernix Therapeutics Holdings, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$397,724 in reported general payments places this provider in the 95th percentile of 503 pain medicine providers in New York.

See all pain medicine providers in New York

Medicare billing

Part B allowed, 2024
$278,882
Medicare patients
286
Services billed
16,815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate33$58,292
Diclofenac Sodium68$48,073
Xtampza ErOxycodone Myristate40$31,775
OxycontinOxycodone Hcl43$27,869
Aimovig AutoinjectorErenumab-Aooe14$25,882
Emgality PenGalcanezumab-Gnlm30$25,578
BotoxOnabotulinumtoxina16$20,200
QuliptaAtogepant13$13,569
Ibuprofen-FamotidineIbuprofen/Famotidine19$13,225
MovantikNaloxegol Oxalate18$13,176
BelbucaBuprenorphine Hcl12$11,991
Oxycodone Hcl352$10,590
Sumatriptan Succinate85$7,712
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen245$7,284
Fentanyl58$4,370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$883$58,29233 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$642$43,76552 claims
AbbVieBotox, Qulipta$189,381$33,76929 claims
Redhill Biopharma Inc.Movantik$71$13,17618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 503 pain medicine providers in New York.

Other pain medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →